Date: 2016-01-07
Type of information: Licensing agreement
Compound: undisclosed immune-modulating agents
Company: Johnson & Johnson Innovation, Janssen Pharmaceuticals, a J&J company (USA - NJ) Chia Tai Tianqing Pharmaceutical Group (China)
Therapeutic area: Infectious diseases - Liver diseases
Type agreement: licensing
Action mechanism:
Disease: hepatitis B
Details: * On January 07, 2016, Johnson & Johnson Innovation and Janssen Pharmaceuticals announced an exclusive license agreement with Chia Tai Tianqing Pharmaceutical Group, a Chinese domestic pharmaceutical company and subsidiary of Sino Biopharma, Ltd. focused on liver diseases, to develop, manufacture and commercialize, outside of China, undisclosed immune-modulating agents to treat human diseases, including curative treatment of chronic Hepatitis B virus (HBV) infection. The agreement follows the recent acquisition of Novira Therapeutics and collaborations with Ichor Medical Systems, Inc. and the University of the Witwatersrand in South Africa, to address the significant unmet medical need inflicted by HBV.
Financial terms:
Latest news:
